ONCOC4, INC. | MedPath

BioNTech Advances Oncology Pipeline with Bispecific Antibody and mRNA Cancer Vaccine Programs

7 months ago

• BioNTech presented clinical data for its bispecific antibody candidate BNT327/PM8002 and mRNA cancer vaccine candidate BNT113, showcasing progress in its oncology pipeline. • Phase 2 dose optimization trials have commenced for BNT327/PM8002 in small-cell lung cancer and triple-negative breast cancer, informing planned Phase 3 trials. • A Phase 2 clinical trial is underway to assess the mRNA-based individualized cancer vaccine candidate autogene cevumeran in high-risk muscle-invasive urothelial cancer. • BioNTech successfully launched variant-adapted COVID-19 vaccines for the 2024/2025 vaccination season and reported Q3 2024 revenues of €1.2 billion.